Insilico Medicine vs MedGenome

Insilico Medicine has a disclosed valuation of $1.2B, while MedGenome's valuation is not publicly available, making a direct size comparison difficult. Insilico Medicine employs 350 people.

Insilico Medicine has raised more in total funding at $403M, compared to MedGenome's $50M — a gap of $353M. Combined, the two companies have completed 3 known funding rounds.

Insilico Medicine holds the higher Awaira Score at 67/100, compared to MedGenome's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 4-point gap that reflects meaningful differences in scale or traction.

Insilico Medicine was founded by Alex Zhavoronkov in 2014. MedGenome was founded by Sam Santhosh in 2013. Visit each company's profile on Awaira for a full founder biography.

Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company leverages artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels. MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system.

MedGenome was founded first in 2013, giving it 1 year of additional market experience. Insilico Medicine was founded later in 2014. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Insilico Medicine has approximately 350 employees, while MedGenome has approximately 200-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Insilico Medicine and MedGenome are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.